CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Iksuda's IKS014 shows 50% response rate in small trial subset of previously treated breast cancer patients

By Public Technologies
  • Iksuda Therapeutics will present preliminary Phase 1 results for IKS014 in HER2-positive solid tumors at the San Antonio Breast Cancer Symposium, December 9, 2026.
  • The treatment showed promising antitumor activity, including in heavily pretreated breast cancer patients who previously received Enhertu.
  • Safety findings indicated manageable side effects, with no treatment-related serious adverse events or fatal events reported.
  • Enrollment continues in expansion cohorts, including breast cancer patients previously treated with Enhertu; the presentation will include updated results.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IP Group plc published the original content used to generate this news brief on November 02, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk